DOI: 10.1128/mBio.00172-20
Article Information
PubMed
Published By
History
- Received January 31, 2020
- Accepted February 11, 2020
- Published online March 31, 2020.
Copyright & Usage
Copyright © 2020 Matthew et al. This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International license.
Editors and / or Reviewers
- Richard Gerald Brennan, Editor, Duke University School of Medicine
Author Information
- Address correspondence to Nese Kurt Yilmaz, Nese.KurtYilmaz{at}umassmed.edu, or Celia A. Schiffer, Celia.Schiffer{at}umassmed.edu.
Ashley N. Matthew and Jacqueto Zephyr contributed equally to this work. Author order was determined both alphabetically and in order of decreasing seniority.
Citation Matthew AN, Zephyr J, Nageswara Rao D, Henes M, Kamran W, Kosovrasti K, Hedger AK, Lockbaum GJ, Timm J, Ali A, Kurt Yilmaz N, Schiffer CA. 2020. Avoiding drug resistance by substrate envelope-guided design: toward potent and robust HCV NS3/4A protease inhibitors. mBio 11:e00172-20. https://doi.org/10.1128/mBio.00172-20.
This article is a direct contribution from Celia A. Schiffer, a Fellow of the American Academy of Microbiology, who arranged for and secured reviews by Stefan Sarafianos, Emory University, and Matthias Gotte, University of Alberta.
